Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07567040 · ClinicalTrials.gov registry record · Phase 3
Delaying the Onset of Nearsightedness Until Treatment (DONUT) Clinical Trial
A Phase 3 study, sponsored by Ohio State University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 664
- Enrollment target
NCT07567040: Recruiting Phase 3 study, sponsored by Ohio State University.
NCT07567040 is a Phase 3 study that is actively recruiting participants, run by Ohio State University. The registered enrollment target is 664 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (14% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07567040, a Phase 3 study, is actively recruiting participants, sponsored by Ohio State University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 664 participants
- Enrollment target
Study Summary
The aims of this clinical trial will test whether or not the onset of nearsightedness is delayed in a group of children randomized to nightly drops in 0.05% atropine in both eyes, in comparison to children who receiving nightly placebo drops in both eyes. The primary outcome is the two-year cumulative incidence of nearsightedness. The second aim of this project will determine whether atropine is associated with slower eye growth in children receiving nightly drops of atropine versus placebo.
Primary Outcome
Cumulative incidence of myopia as measured by cycloplegic autorefraction comparison between treatment and placebo
Interventions
- DRUG Placebo
- DRUG Atropine Sulfate 0.05% Oph Soln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 664 participants |
| Start Date | 2026-05-27 |
| Est. Completion | 2028-05-15 |
| Phase | Phase 3 |
What NCT07567040 shows while recruiting
NCT07567040 is an interventional study that assigns participants to a tested intervention. The registered 664 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (14% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07567040 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07567040 about?
NCT07567040 is a clinical study titled "Delaying the Onset of Nearsightedness Until Treatment (DONUT) Clinical Trial". The aims of this clinical trial will test whether or not the onset of nearsightedness is delayed in a group of children randomized to nightly drops in 0.05% atropine in both eyes, in comparison to children who receiving nightly placebo drops in both eyes. The primary outcome is the two-year cumulati...
What is the current status of trial NCT07567040?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 664 participants. The study started on 2026-05-27. Estimated completion is 2028-05-15.
What interventions are being tested in trial NCT07567040?
The interventions under investigation include: Placebo (DRUG), Atropine Sulfate 0.05% Oph Soln (DRUG).
Who is sponsoring clinical trial NCT07567040?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07567040's enrollment target sits among peer trials
664 553rd of 2000 higher than 1,448 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06607341 · 664 participants · NA
Community Engagement Alliance Against Disparities
- NCT04064060 · 665 participants · Phase 3
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
- NCT07164443 · 663 participants · Phase 3
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- NCT06328647 · 666 participants · NA
Quantra Point-of-Care Hemostasis Monitoring
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI